Diaceutics (LON:DXRX) Trading 9.4% Higher – Here’s What Happened

Diaceutics PLC (LON:DXRX) traded up 9.4% on Tuesday . The stock traded as high as GBX 186.90 and last traded at GBX 186. Approximately 1,307,491 shares changed hands during mid-day trading, an increase of 546% from the average session volume of 202,378 shares. The stock had previously closed at GBX 170.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reissued a “buy” rating and issued a GBX 215 price objective on shares of Diaceutics in a research note on Tuesday. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of GBX 215.

Diaceutics Stock Performance

The stock has a 50-day moving average of GBX 145.09 and a 200 day moving average of GBX 150.64. The stock has a market cap of £157.84 million, a PE ratio of 1,690.91 and a beta of 0.88. The company has a quick ratio of 9.92, a current ratio of 3.43 and a debt-to-equity ratio of 2.85.

Diaceutics (LON:DXRX) last issued its earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share (EPS) for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. Equities analysts predict that Diaceutics PLC will post 1.0107919 EPS for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.